IMMUNOGEN INC Form 8-K August 06, 2009

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 6, 2009

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts (State or other jurisdiction of incorporation) **0-17999** (Commission File Number)

04-2726691 (IRS Employer Identification No.)

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices) (Zip Code)

Edgar Filing: IMMUNOGEN INC - Form 8-K

Registrant s telephone number, including area code: (781) 895-0600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: IMMUNOGEN INC - Form 8-K

ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION

On August 6, 2009, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the company s financial results for the quarter and fiscal year ended June 30, 2009. The press release announcing financial results for the quarter and fiscal year ended June 30, 2009 is included as Exhibit 99.1 and incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d): The following exhibit is being furnished herewith:

Exhibit No. Exhibit

99.1 Press Release of ImmunoGen, Inc. dated August 6, 2009

2

Edgar Filing: IMMUNOGEN INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc. (Registrant)

Date: August 6, 2009 /s/ Gregory Perry

> Gregory Perry Senior Vice President and Chief Financial Officer

3